|
|
|
MIRA INFORM REPORT
|
Report No. : |
485919 |
|
Report Date : |
18.01.2018 |
IDENTIFICATION DETAILS
|
Name : |
PAO BIOSINTEZ |
|
|
|
|
Formerly Known As : |
OAO BIOSINTEZ |
|
|
|
|
Registered Office : |
Druzhby Street 4, Penzenskaya Region, 440033, Penza |
|
|
|
|
Country : |
Russia |
|
|
|
|
Financials (as on) : |
31.12.2016 |
|
|
|
|
Date of Incorporation : |
26.11.1992 |
|
|
|
|
Com. Reg. No.: |
OGRN
1025801102502 |
|
|
|
|
Legal Form : |
Public
Joint Stock Company |
|
|
|
|
Line of Business : |
·
Manufacture of basic pharmaceutical products ·
Manufacture of pharmaceutical preparations |
|
|
|
|
No. of Employees : |
1,510 |
RATING & COMMENTS
(Mira Inform has adopted New Rating mechanism w.e.f. 23rd
January 2017)
|
MIRA’s Rating : |
A |
|
Credit Rating |
Explanation |
Rating Comments |
|
A |
Acceptable Risk |
Business dealings permissible with
moderate risk of default |
|
Maximum Credit Limit : |
RUB (RUBLE) 286,000 |
|
|
|
|
Status : |
Satisfactory |
|
|
|
|
Payment Behaviour : |
No Complaints |
|
|
|
|
Litigation : |
Clear |
NOTES :
Any query related to this report can be made
on e-mail : infodept@mirainform.com
while quoting report number, name and date.
ECGC Country Risk Classification List
|
Country Name |
Previous Rating (30.06.2017) |
Current Rating (30.09.2017) |
|
Russia |
A2 |
A2 |
|
Risk Category |
ECGC
Classification |
|
Insignificant |
A1 |
|
Low Risk |
A2 |
|
Moderately Low Risk |
B1 |
|
Moderate Risk |
B2 |
|
Moderately High Risk |
C1 |
|
High Risk |
C2 |
|
Very High Risk |
D |
RUSSIA - ECONOMIC OVERVIEW
Russia has undergone significant changes since the collapse of the Soviet Union, moving from a centrally planned economy towards a more market-based system. Both economic growth and reform have stalled in recent years, however, and Russia remains a predominantly statist economy with a high concentration of wealth in officials' hands. Economic reforms in the 1990s privatized most industry, with notable exceptions in the energy, transportation, banking, and defense-related sectors. The protection of property rights is still weak, and the state continues to interfere in the free operation of the private sector.
Russia is one of the world's leading producers of oil and natural gas, and is also a top exporter of metals such as steel and primary aluminum. Russia's reliance on commodity exports makes it vulnerable to boom and bust cycles that follow the volatile swings in global prices. The economy, which had averaged 7% growth during the 1998-2008 period as oil prices rose rapidly, has seen diminishing growth rates since then due to the exhaustion of Russia’s commodity-based growth model.
A combination of falling oil prices, international sanctions, and structural limitations pushed Russia into a deep recession in 2015, with the GDP falling by close to 4%. The downturn continued through 2016, with GDP contracting by 0.6%. Government support for import substitution has increased recently in an effort to diversify the economy away from extractive industries. Russia is heavily dependent on the movement of world commodity prices and the Central Bank of Russia estimates that if oil prices remain below $40 per barrel in 2017, the resulting shock would cause GDP to fall by up to 5%.
|
Source
: CIA |
SUMMARY
|
||||||||
COMPANY NAME
|
PAO Biosintez |
|||||||
|
|
||||||||
ADDRESS
|
Building |
Street |
Area |
PO Box |
||||
|
Biosintez Building |
Druzhby Street 4 |
Penzenskaya Region |
440033 Penza |
|||||
TEL/FAX
|
Verified Phones: +(7 8412) 577 272 / +(7 8412) 583 244
/ +(7 8412) 583 269 / Fax: +(7
8412) 583 244 |
|||||||
EMAIL/WEBSITE
|
Email: biosintez.info@sunpharma.com / Website: www.biosintez.com |
|||||||
ACTIVITY
|
NACE 2110 - Manufacture of basic pharmaceutical products; NACE 2120 -
Manufacture of pharmaceutical preparations. |
|||||||
PRINCIPAL
|
Workforce |
|||||||
|
Managing Director
|
1,510 |
|||||||
LEGAL INFO
|
Date Of Est. |
Reg. No. |
Legal Form |
Status |
||||
|
26/11/1992 |
OGRN 1025801102502 |
Public Joint Stock Company |
Active |
|||||
CAPITAL
|
CURRENCY |
AMOUNT |
||||||
|
RUB (RUBLE) |
286,000 |
|||||||
OPINION ON MAX CREDIT
|
CURRENCY |
AMOUNT |
||||||
|
RUB (RUBLE) |
286,000 |
|||||||
IDENTIFICATION
|
|||
CO. NAME
|
PAO
Biosintez |
||
TRADEMARK
|
Biosintez |
||
ALSO KNOWN NAME (S)
|
PJSC Biosintez / Public Joint Stock Company Biosintez / OJSC Biosintez |
||
FORMER NAME
|
OAO
Biosintez |
||
BUILDING
|
Biosintez Building |
||
STREET
|
Druzhby Street 4 |
||
AREA
|
Penzenskaya Region |
||
POSTAL ADDRESS
|
440033
Penza |
||
CITY
|
Penza |
||
COUNTRY
|
Russia |
||
TELEPHONE
|
+(7 8412) 577 272 / +(7 8412) 583
244 / +(7 8412) 583 269 (Procurement Department) / +(7 8412)
583 211 (Chief Accountant) / +(7 8412) 577 226 / +(7 8412) 583 333 (HR
Department) / +(7 8412) 583 087 (Head of Finance Department) / Mobile +(7 902) 205 4051 |
||
FAX
|
+(7 8412) 583 244 |
||
VERIFIED EMAIL
|
biosintez.info@sunpharma.com / olga.grishina@sunpharma.com
/ tefanova_tu@biosintez.com /
alexander.larkin@sunpharma.com
|
||
WEBSITE
|
www.biosintez.com |
||
BUSINESS HOURS
|
DAYS |
OFFICE HOURS |
BREAK TIME |
|
Mon-Fri |
09:00-18:00 |
13:00-14:00 |
|
REGISTERED ADDRESS
|
Druzhby Street 4, Penzenskaya
Region, 440033 Penza, Russia |
||
SENIOR
PERSONNEL
|
||
MANAGEMENT
|
NAME |
POSITION |
|
Arun Kumar
Rajput |
Chairman |
|
|
Board of Directors Arvind Kumar Vivek Mittal Arvind Abrool Aleksand Borisovich Voloshinov Management Dmitriy Vasilevich Boldov Lyudmila Evgenievna Leontieva Sergey Yurievich Tokarev Olga Grishina Tatyana Yurievna Tefanova Svetlana Aleksandrovna Gorbunova Larisa Evgenievna Rassadina Elena Gennadievna Bystrova Anna Nikolaevna Kurmaeva Anton Dmitrievich Kedrov Tatyana Aleksandrovna Afonina Aleksandr Anatolievich Larkin Aleksey Aleksandrovich Gorshenin Aleksandr Vladimirovich Zobnin
|
Member of the Board Member of the Board Member of the Board Member of the Board Managing Director Deputy Managing Director /
Production Head of Economics Department Head of Finance Department Chief Accountant Deputy Managing Director / Quality Deputy Managing Director Chief Engineer HR Director Head of Procurement Department Head of Sales Department Procurement Manager Head of Legal Department Head of Logistics Department |
|
WORKFORCE
|
NO. OF EMPLOYEES |
PERIOD |
|
1,510 |
01.2018 |
|
|
1,781 52,700
(Sun Pharma Group) |
01.2017 03.2016 |
|
FINANCIAL
SUMMARY
|
||
REVENUE
|
31/12/2016 |
31/12/2015 |
|
RUB 2,925,057,000 |
RUB 3,208,263,000 |
|
NET PROFIT / (LOSS)
|
31/12/2016 |
31/12/2015 |
|
RUB (29,279,000) |
RUB (65,963,000) |
|
PROFIT BEFORE TAX
|
RUB
133,617,000 as of 30/09/2017 |
|
REVENUE (QUARTERLY)
|
RUB 2,006,588,000 as of
30/09/2017 |
|
NET PROFIT (QUARTERLY)
|
RUB 77,612,000
as of 30/09/2017 |
|
STOCK/INVENTORIES
|
RUB 630,404,000 as of 30/09/2017 |
|
LEGAL
STATUS
|
||
INCORPORATION
|
26/11/1992 |
|
REGISTRATION NO.
|
C.R. NUMBER |
ISSUED BY |
|
OGRN 1025801102502 |
Federal Tax Service |
|
OTHER REGISTRATION NO.
|
INN
5834001025 (Tax Code) / KPP 583401001 /
OKPO 480550 (Statistics Code) / OKTMO 56701000001 |
|
AUTHORISED CAPITAL
|
AMOUNT |
CURRENCY |
|
286,000 |
RUBLE |
|
PAID-UP CAPITAL
|
AMOUNT |
CURRENCY |
|
286,000 |
RUBLE |
|
LEGAL FORM
|
Public
Joint Stock Company |
|
BUSINESS HISTORY
|
The
company was incorporated in Russian Federation on 26 November 1992 under the
name OAO Biosintez with the following shareholding structure: OOO
Intermedfarm – 34.1% ZAO MFPDK
Biotek – 39.9% OAO
Bioprepart & OAO Farmatsia – 26% Subject’s
operations can be traced back to 1955. On 15 June
2016, subject changed its name to the present style. In December 2016,
subject’s shareholding structure changed to the present. |
|
STATUS
|
Active |
|
SHAREHOLDERS
|
NAME |
PERCENTAGE |
|
1. Ranbaxy
(Netherlands) B.V. Polaris Avenue 87, 2132 JH Hoofddorp the Netherlands Est.: 14/12/1993 2. Other
minority shareholders Ultimate
parent company Sun
Pharmaceutical Industries Limited Sun
House CTS No.
201 B/1, Western
Express Highway, Goregaon
(E), Mumbai
400063 Tel : +(91
22) 4324 4324 Fax : +(91
22) 4324 4343 Sun Pharma
is a multinational pharmaceutical company
headquartered in Mumbai, Maharashtra that manufactures and sells pharmaceutical
formulations and active pharmaceutical ingredients (APIs) primarily in India
and the United States. The company offers formulations in various therapeutic
areas, such as cardiology, psychiatry, neurology, gastroenterology and
diabetology. It also provides APIs such as warfarin, carbamazepine, etodolac,
and clorazepate, as well as anticancers, steroids, peptides, sex hormones,
and controlled substances. Sun Pharmaceuticals was established by Mr.
Dilip Shanghvi * in 1983 in Vapi with five products to treat psychiatry
ailments. Cardiology products were introduced in 1987 followed by
gastroenterology products in 1989. Today, it is the largest chronic
prescription company in India and a market leader in psychiatry, neurology,
cardiology, orthopedics, ophthalmology, gastroenterology and nephrology. The
2014 acquisition of Ranbaxy has made the company the largest pharma company
in India, the largest Indian pharma company in the US, and the 4th largest
specialty generic company globally. * Mr.
Dilip Shanghvi (born 1 October 1955) is an Indian businessman and one of the
country's richest people. He founded Sun Pharmaceuticals with a partner,
Pradeep Ghosh. The Government of India awarded him the civilian honour of the
Padma Shri in 2016. India Today magazine ranked him #8th in India's 50 Most
powerful people of 2017 list. As
of September 2017, he had a net worth of $11.6 billion. |
85.1% 14.9% |
|
OPERATION
|
||
BANKERS
|
PAO Sberbank Suvorova Street 81 Penza 440000 Telephone: +(7 8412) 429 800 / 429
979 Fax : +(7 8412) 429 979 Acc. No.: 30101810000000000635 BIK : 045655635 |
|
AUDITORS
|
OOO Rais Audit Koshtoyantsa Street 10 Moscow 119454 Russia Telephone: +(7 499) 131 7177 C.R. No. : OGRN 1037789069230 Tax Code: INN 7729501819 |
|
ACTIVITY CODE (NACE)
|
2110 - Manufacture of basic
pharmaceutical products; 2120 - Manufacture of pharmaceutical preparations. |
|
LINE OF BUSINESS
|
Manufacturers of pharmaceutical products including
powders for injections, injections and infusions, tablets, ointments and
suppositories as well as substance. The composition of the extensive nomenclature
contains preparations of various pharmacotherapeutic groups, including: - Antibiotics; - Antihemorrhoidal agents; - Antimicrobial agents of different groups; - Bronchodilators; - Vitamins; - Hypoglycemic agents; - Diuretics; - Cholagogue and enzymes; - Blood Substitutes and Plasma Substituting
agents; - Metabolic and antioxidant agents; - Nootropics; - Preparations of potassium and magnesium; - Antiallergic agents; - Antiviral drugs; - Anti-inflammatory, analgesic and antipyretic
agents; - Antifungal means; - Anti-TB drugs; - Regenerating agents; - Sedatives; - Cardiovascular drugs; - Spasmolytic drugs; - Means of carbohydrate nutrition; - Means that affect immunity. |
|
IMPORT FROM
|
LIST OF COUNTRIES |
PAYMENT
TERMS |
|
1. China
(80%) 2. India
(occasionally) 3.
European countries |
Bill of
exchange Bill of
exchange |
|
EXPORT TO
|
CIS
countries, Kazakhstan, Uzbekistan, Azerbaijan, Georgia, Armenia, Tajikistan,
Kyrgyzstan, Turkmenistan, Baltic countries, Eastern Europe and Far East Asian
countries. |
|
FACILITIES
|
Owned premises
comprising administrative offices, a manufacturing units as well as warehouse
facilities located at the heading address. |
|
RELATED COMPANIES
|
A member
of Sub Pharm Group of Companies managed by Sun Pharmaceutical Industries
Limited, India. Associates 1. SPIL De Mexico S.A. DE C.V.
Mexico 2. Sun Pharmaceutical (Bangladesh)
Limited
Bangladesh 3. Sun Pharma Holdings
Mauritius 4. Sun Pharma DE Mexico S.A. DE C.V.
Mexico 5. Sun Pharmaceutical Peru Sociedad
Anonima
Cerrada
Peru 6. OOO Sun Pharmaceutical Industries
Limited
Russia 7. Green Eco Development Centre
Limited
India 8. Sun Pharma DE Venezuela, C.A.
Venezuela 9. Sun Pharma Laboratories Limited
India 10.Neetnav Real Estate Private Limited
India 11.Skisen Labs Private Limited
India 12.Softdeal Trading Company Private
Limited
India 13.Faststone Mercantile Company
Private Limited
India 14.Realstone Multitrade Private
Limited
India 15.Ranbaxy Drugs Limited
India 16.Vidyut Investments Limited
India 17.Gufic Pharma Limited
India 18.Ranbaxy (Malaysia) SDN. BHD.
Malaysia 19.Ranbaxy Nigeria Limited
Nigeria 20.Ranbaxy Pharmacie Generiques
France 21.Sun Pharmaceutical Industries,
Inc.
USA 22.Sun Farmaceutica do Brasil Ltda.
Brazil 23.Foundation for Disease
Elimination and Control
of India
India 24.Universal Enterprises Private
Limited
India 25.Office Pharmaceutique Industriel
Et
Hospitalier
France 26.Sun Pharma Global (FZE)
UAE 27.Sun Pharmaceuticals (SA) (Pty)
Ltd.
South Africa 28.Sun Laboratories (FZE)
UAE 29.ALKALOIDA Chemical Company Zrt.
Hungary 30.Sun Pharmaceutical Industries
(Australia) Pty
Ltd.
Australia 31.Sun Global Development (FZE)
UAE 32.Sun Pharmaceuticals Korea Ltd.
South Korea 33.Sun Global Canada Pty. Ltd.
Canada 34.Sun Pharma Philippines, Inc.
Philippines 35.Sun Pharma Healthcare (FZE)
UAE 36.Sun Pharma Japan Ltd.
Japan 37.Sun Pharma East Africa Limited
Kenya 38.Caraco Pharmaceuticals Private
Limited
India 39.Pharmalucence, Inc.
USA 40.The Taro Development Corporation
USA 41.DUSA Pharmaceuticals, Inc.
USA 42.Chattem Chemicals, Inc.
USA 43.Mutual Pharmaceutical Company,
Inc
USA 44.PI Real Estate Ventures, LLC
USA 45.Morley & Company, Inc.
USA 46.URL PharmPro, LLC
USA 47.Dungan Mutual Associates, LLC
USA 48.Taro Pharmaceutical Industries
Ltd.
Israel 49.Sun Pharmaceuticals UK Limited
UK 50.Sun Pharmaceuticals France
France 51.Sun Pharmaceutical Industries
(Europe) B.V.
The Netherlands 52.Sun Pharmaceuticals Germany GmbH
Germany 53.Sun Pharmaceuticals Italia S.R.L.
Italy 54.Aditya Acquisition Company
Limited
Israel 55.Alkaloida Sweden AB
Sweden 56.Sun Pharma Switzerland Ltd.
Switzerland 57.Taro Pharmaceuticals North
America, Inc.
Cayman Islands 58.Taro Pharmaceuticals U.S.A., Inc.
USA 59.Taro International Limited
Israel 60.Taro Pharmaceuticals Europe B.V.
The Netherlands 61.Taro Pharmaceuticals Inc.
Canada 62.3 Skyline LLC
USA 63.One Commerce Drive LLC
USA 64.Taro Pharmaceutical Laboratories
Inc.
USA 65.Taro Pharmaceuticals (UK) Limited
UK 66.Taro Pharmaceuticals India
Private Limited
India 67.Taro Pharmaceuticals Ireland
Limited
Ireland 68.Taro Pharmaceuticals Canada Ltd.
Canada 69.S. C “Terapia” S.A.
Romania 70.Laboratorios Ranbaxy S.L.U.
Spain 71.AO Ranbaxy (Formerly known as ZAO
Ranbaxy)
Russia 72.Ranbaxy Pharmaceuticals Ukraine
LLC
Ukraine 73.Ranbaxy Pharmaceuticals (Pty)
Ltd.
South Africa 74.Ranbaxy South Africa Proprietary
Limited
South Africa 75.Ranbaxy Holdings (UK) Limited
UK 76.Ranbaxy Farmaceutica Ltda
Brazil 77.Ranbaxy (Thailand) Co. Ltd.
Thailand 78.Ranbaxy (Poland) Sp.z.o.o.
Poland 79.Sun Pharmaceutical Industries
S.A.C.
Peru 80.Ranbaxy Egypt Limited
Egypt 81.Ranbaxy Italia S.P.A.
Italy 82.Ranbaxy (U.K.) Limited
UK 83.Sun Pharma ANZ Pty Ltd (Formerly
known as
Ranbaxy Australia Pty Limited)
Australia 84.Ranbaxy Ireland Limited
Ireland 85.Sun Pharmaceuticals Morocco LLC
(Formerly
known as Ranbaxy Morrocco LLC)
Morocco 86.Ranbaxy Pharmaceuticals Canada
Inc.
Canada 87.Basics GmbH
Germany 88.Ranbaxy GmbH
Germany 89.Be-Tabs Invesments Proprietary
Limited
South Africa 90.Sonke Pharmaceuticals Pty Limited
South Africa 91.Ranbaxy Inc.
USA 92.Ranbaxy Europe Limited
UK 93.Ranbaxy Laboratories Inc.
USA 94.Ranbaxy Pharmaceuticals Inc.
USA 95.Ohm Laboratories Inc.
USA 96.Ranbaxy Signature LLC
USA 97.Insite Vision Incorporated
USA 98.Insite Vision Limited
UK 99.Rexcel Egypt LLC
Egypt 100.Sun Pharma Medisales Private
Limited
(Formerly known as Solrex Pharmaceuticals
Company, Partnership firm)
India 101.2 Independence Way LLC
USA 102.Ocular Technologies SARL
Switzerland 103.Sun Pharmaceuticals Holdings
USA, Inc
USA 104.Sun Pharmaceutical Medicare
Limited
India 105.Trumpcard Advisors and Finvest
LLP
India 106.Zenotech Laboratories Limited
India 107.Medinstill LLC
USA 108.Fraizer Healthcare VII, L.P.
USA 109.Versant Venture Capital V, L.P.
USA 110.SC Pharmaceuticals Inc.
USA 111.Generic Solar Power LLP
India 112.S&I Ophthalmic LLC
USA 113.Artes Biotechnology GmbH
Germany 114.MSD - Sun LLC
USA |
|
FINANCIAL
INFORMATION
|
||
CURRENCY
|
RUBLE (RUB) |
|
PERIOD
|
31/12/2016 |
31/12/2015 |
CURRENT ASSETS
|
1,257,688,000 |
1,758,796,000 |
STOCK/INVENTORIES
|
480,031,000 |
619,540,000 |
NON-CURRENT ASSETS
|
2,551,010,000 |
2,515,951,000 |
SHORT-TERM LIABILITIES
|
1,354,053,000 |
1,441,228,000 |
EQUITY
|
741,356,000 |
770,635,000
|
BALANCE TOTAL
|
3,808,698,000 |
4,274,747,000 |
REVENUE
|
2,925,057,000
|
3,208,263,000 |
NET PROFIT / LOSS
|
(29,279,000) |
(65,963,000) |
NOTES
|
Balance
sheets as at 31 December 2016 showed : 31/12/2016 31/12/2015 (in thousands of RUBLE) ASSETS
Non-current
assets Intangible
assets 2,764 3,015 Results
of research and development 9,304 8,239 Fixed
assets 1,890,506 1,954,366 Financial
investments 1,069 2,000 Deferred
tax assets 149,680 134,917 Unfinished
and unregistered R&D
and unfinished operations for
acquisition of intangible
assets 87,876 69,951 Unfinished
capital investments in
fixed asset items 357,851 279,640 Other
non-current assets 51,960 63,823 Total
non-current assets 2,551,010 2,515,951 Current
assets Reserves 480,031 619,540 Including: raw
and other materials and
other similar valuables 249,440 265,332 costs
in work-in- progress 30,904 76,660 finished
products and goods
for resale 195,381 270,811 other
reserves and 4,306 6,737 costs Value added tax on acquired valuables 20,457 12,019 Accounts receivable (for which payments are expected more than 12 months after the reporting date) 6,516 9,760 Accounts receivable (for which payments are expected within 12 months after the reporting date) 577,919 1,115,862 Cash and cash equivalents 172,741 1,588 Other current assets 24 27 Total current assets 1,257,688 1,758,796 TOTAL ASSETS
3,808,698 4,274,747 EQUITY AND LIABILITIES Equity and provisions Charter capital 286 286 Revaluation of non-current assets 311,397 321,957 Reserve capital 14 72 Retained profit (uncovered Loss) 429,659 448,320 Total equity 741,356 770,635 Long-term liabilities Borrowed funds
1,582,467 1,960,567 Deferred tax liabilities 130,821 102,316 Other liabilities 1 1 Total long-term liabilities
1,713,289 2,062,884 Short-term liabilities Borrowed funds 999,576 249,394 Accounts payable 287,022 1,164,561 Estimated liabilities 67,452 27,273 Other liabilities 0 0 Total short-term Liabilities
1,354,053 1,441,228 TOTAL EQUITY AND INCOME STATEMENT Revenue
2,925,057 3,208,263 Cost of sales
(2,114,136) (2,290,906) Gross profit 810,921 917,357 Selling expenses (66,258) (81,641) Administrative expenses
(206,022) (216,312) Profit (loss) of sales 538,641 619,404 Income from participation in other organization 0 1 Interest receivable 92 20 Interest payable (83,930) (72,872) Other incomes 133,855 67,082 Other expenses
(594,894) (721,179) Profit(loss) before tax (6,236) (107,544) Permanent tax liabilities (assets) 14,953 8,082 Changes in deferred tax liabilities (28,469) (30,293) Changes in deferred tax assets 14,763 82,490 Other items (9,337) (10,616) Net profit(loss) (29,279) (65,963) The following Consolidated Balance Sheets as at 31
March 2017 applies to subject’s ultimate parent company, Sun Pharmaceutical
Industries Limited:
31/03/2017 31/03/2016
(in millions of INR) ASSETS
Non-current
assets Property,
plant and equipment 84,952.9 75,831.4 Capital
work-in- progress 15,647.6 12,034.6 Goodwill
(Net) 55,362.2 56,347.4 Other
intangible assets 36,436.6 26,543.7 Intangible assets under development 12,366.2 9,719.9 Investments in associates 4,605.4 3,008.8 Investments in joint ventures 429.5 655.0 Financial assets Investments 4,575.1 7,496.9 Loans 7 698.1 1,073.2 Other financial assets
6,452.2 9,809.9 Deferred tax
assets (Net) 24,928.2 31,489.9 Income tax assets (Net) 31,250.1 15,726.2 Other non-current assets 6,861.8 6,152.8 Total non-current assets 284,565.9 255,889.7 Current Assets Inventories 68,328.1 64,225.4 Financial assets Investments 2,308.8 7,138.1 Trade receivables 72,026.1 67,756.6 Cash and cash equivalents 86,628.0 80,751.4 Bank balances other than
(iii) above 64,780.4 51,065.1 Loans 10,190.8 10,715.5 Other financial assets 2,258.5 890.8 Other current assets 22,949.9 16,798.2 329,470.6 299,341.1 Assets classified as held
for sale 65.9 71.9 Total current assets 329,536.5 299,413.0 TOTAL
ASSETS 614,102.4 555,302.7 EQUITY
AND LIABILITIES Equity
Equity
share capital 2,399.3 2,406.6 Share suspense account - - Other equity 363,997.4 327,418.2 Equity attributable to the owners
of the Company 366,396.7 329,824.8 Non-controlling
interests 37,908.6 40,852.5 Total equity 404,305.3 370,677.3 Liabilities Non-current
liabilities Financial
liabilities Borrowings 14,360.8 31,103.0 Trade payables - - Other financial liabilities 1,048.0 1,842.2 Provisions 12,111.1 18,958.6 Deferred
tax liabilities
(Net) 3,147.9 1,027.7 Other non-current liabilities 259.1 254.3 Total non-current liabilities 30,926.9 53,185.8 Current liabilities Financial
liabilities Borrowings 66,549.2 52,061.2 Trade payables 43,953.9 35,829.2 Other financial liabilities 22,116.3 6,873.3 Other current liabilities 4,620.5 4,469.4 Provisions 40,159.1 29,734.4 Current tax liabilities
(Net) 1,471.2 2,472.1 Total current liabilities 178,870.2 131,439.6 Total liabilities 209,797.1 184,625.4 TOTAL
EQUITY AND LIABILITIES 614,102.4 555,302.7 CONSOLIDATED
STATEMENT OF PROFIT AND LOSS
31/03/2017 31/03/2016
(in millions of INR) Revenue
from operations 315,784.4 284,870.3 Other income 6,231.5 6,582.5 Total income 322,015.9 291,452.8 Expenses Cost of materials consumed 51,246.1 41,816.3 Purchases of stock-in-trade 32,777.6 25,425.2 Changes in inventories of finished
goods, stock-in-trade and
work-in-progress (2,716.3)
(3,937.7) Employee benefits expense 49,023.0 47,723.1 Finance costs 3,998.0 5,232.4 Depreciation and amortisation
expense 12,647.5 10,375.3 Other
expenses 84,561.3 92,260.2 Total expenses 231,537.2 218,894.8 Profit before exceptional items
and tax 90,478.7 72,558.0 Exceptional items - (6,851.7) Profit before tax 90,478.7 65,706.3 Tax expense Current
tax 4,046.4 11,954.1 Deferred tax charge/(credit) 8,069.3 (2,816.4) Total tax expense 12,115.7 9,137.7 Profit for the year before
share of profit/(loss) of associates and
joint ventures 78,363.0 56,568.6 Share of profit/(loss) of associates 299.6 (18.7) Share of profit/(loss) of
joint ventures (200.3) 33.2 Profit for the year before non-controlling
interests 78,462.3 56,583.1 Non-controlling interests 8,818.6 11,126.0 Profit for the year attributable
to owners of the
Company 69,643.7 45,457.1 |
|
PAYMENT
|
||
CREDIT OPINION
|
We
consider it is acceptable to deal with subject for LARGE amounts. |
|
CREDIT LIMIT
RECOMMENDATION
|
CURRENCY |
AMOUNT |
|
RUBLE |
90,000,000
(higher amounts may be
considered with assurances from the parent company) |
|
FINANCIAL STRENGTH
|
Low |
|
EMPLOYEE RANGE
|
ER1 |
|
SPECIAL
REMARKS
|
|
INTERVIEWED
|
Tatyana Yurievna Tefanova (Chief Accountant). |
COMMENTS
|
You enquired on: BIOSINTEZ A SUN PHARMA COMPANY. Please note
that the correct registered name is as per heading. |
FOREIGN EXCHANGE RATES
|
Currency |
Unit
|
Indian Rupees |
|
US Dollar |
1 |
INR 63.98 |
|
|
1 |
INR 88.13 |
|
Euro |
1 |
INR 78.35 |
|
RUB |
1 |
INR 1.12 |
Note :
Above are approximate rates obtained from sources believed to be correct
INFORMATION DETAILS
|
Analysis Done by
: |
PRI |
|
|
|
|
Report Prepared
by : |
SYL |
RATING EXPLANATIONS
|
Credit Rating |
Explanation |
Rating Comments |
|
A++ |
Minimum Risk |
Business dealings permissible with minimum
risk of default |
|
A+ |
Low Risk |
Business dealings permissible with low
risk of default |
|
A |
Acceptable Risk |
Business dealings permissible with
moderate risk of default |
|
B |
Medium Risk |
Business dealings permissible on a regular
monitoring basis |
|
C |
Medium High Risk |
Business dealings permissible preferably
on secured basis |
|
D |
High Risk |
Business dealing not recommended or on
secured terms only |
|
NB |
New Business |
No recommendation can be done due to
business in infancy stage |
|
NT |
No Trace |
No recommendation can be done as the
business is not traceable |
NB is stated where there is insufficient information to facilitate rating. However, it is not to be considered as unfavourable.
This score serves as a reference to assess
SC’s credit risk and to set the amount of credit to be extended. It is
calculated from a composite of weighted scores obtained from each of the major
sections of this report. The assessed factors are as follows:
·
Financial
condition covering various ratios
·
Company
background and operations size
·
Promoters
/ Management background
·
Payment
record
·
Litigation
against the subject
·
Industry
scenario / competitor analysis
·
Supplier
/ Customer / Banker review (wherever available)
This report is issued at
your request without any risk and responsibility on the part of MIRA INFORM
PRIVATE LIMITED (MIPL) or its officials.